Definium 制药

最新新闻

• 评级变动
  BofA Securities Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $78
  \u5e02\u573a\u8d44\u8baf · 2026/9/19
• Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $67
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  CCORF Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $64
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Wells Fargo Initiates Definium Therapeutics(DFTX.US) With Buy Rating, Announces Target Price $68
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $64 to $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• Maxim Group Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 公司公告
  Mind Medicine: Mind Medicine (MindMed) Inc. - Name/Symbol/CUSIP Change Option Symbol: MNMD New Symbol: DFTX
  OCC · 2026/1/15
• 评级变动
  BofA Securities Initiates Definium Therapeutics(DFTX.US) With Buy Rating, Announces Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $50 to $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  RBC Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $66
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Piper Sandler Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  H.C. Wainwright Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $90
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Maxim Group Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• 评级变动
  Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
  TipRanks · 2026/9/19
• A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $91
  \u5e02\u573a\u8d44\u8baf · 2026/9/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。